腺苷脱氨酶缺陷基因治疗的长期安全性和有效性
该研究纳入2012至2019年在美国和英国接受慢病毒基因治疗的62例腺苷脱氨酶缺陷所致重症联合免疫缺陷患者,中位随访7.5年、共474患者年。总生存率100%,无事件生存率95%(59/62);59例6个月时成功基因标记植入者均持续未接受酶替代治疗,58例(98%)停用IgG替代治疗。
要点
- 腺苷脱氨酶缺陷所致重症联合免疫缺陷患者接受慢病毒基因治疗后总生存率100%,无事件生存率95%(59/62)。
- 59例6个月时成功基因标记植入者持续未接受酶替代治疗,基因标记、ADA酶活性、代谢解毒和免疫重建稳定。
- 58例(98%)停用IgG替代治疗且对疫苗接种有强反应,无白细胞增殖事件或克隆扩增。
核心结论
- 这些长期结果在较大患者队列中显示自体CD34+造血干细胞慢病毒基因治疗对腺苷脱氨酶缺陷所致重症联合免疫缺陷具有持续临床有效性和安全性,表明其为治愈性治疗。
研究设计与样本
- 2012年至2019年,研究纳入接受白消安非清髓预处理后输注体外慢病毒载体转导的自体CD34+造血干细胞的腺苷脱氨酶缺陷所致重症联合免疫缺陷患者。
- 共治疗62例患者,美国33例、英国29例,随访共474患者年,中位随访7.5年。
- 主要疗效终点为总生存率和无事件生存率(无事件生存定义为无补救性异基因造血干细胞移植、无需重新开始酶替代治疗且无需额外基因治疗的生存)。
- 次要终点包括未接受免疫球蛋白替代治疗、破伤风或肺炎球菌疫苗保护性滴度存在以及持续停用真菌或病毒预防。
主要发现
- 总生存率为100%,无事件生存率为95%(59/62)。
- 59例6个月时成功基因标记植入的患者至末次随访均持续未接受酶替代治疗,且基因标记、ADA酶活性、代谢解毒和免疫重建稳定。
- 59例中58例(98%)停用IgG替代治疗,并有证据显示对疫苗接种有强反应。
- 无患者发生白细胞增殖事件或克隆扩增。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a life-threatening inborn error of immunity for which lentiviral gene therapy has been investigated in clinical trials. METHODS: Between 2012 and 2019, we treated patients who had ADA-SCID with busulfan nonmyeloablative conditioning followed by transplantation with autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human ADA. The primary efficacy end points were overall survival and event-free survival (defined as survival free from rescue allogeneic hematopoietic stem-cell transplantation, reinitiation of enzyme-replacement therapy, and additional gene therapy). Secondary end points included no receipt of immunoglobulin-replacement therapy, the presence of protective titers to tetanus or pneumococcal vaccines, and sustained discontinuation of fungal or viral prophylaxis. We now report the long-term results from this cohort representing 474 patient-years of follow-up, with a median follow-up of 7.5 years. RESULTS: We treated 62 patients with ADA-SCID in the United States (33 patients) and the United Kingdom (29 patients). Overall survival was 100%, and event-free survival was 95% (59 of 62 patients). All 59 patients who had successful gene-marked engraftment at 6 months have continued not to receive enzyme-replacement therapy and have had stable gene marking, ADA enzyme activity, metabolic detoxification, and immune reconstitution through the last follow-up; 58 of these patients (98%) discontinued IgG replacement therapy and have evidence of a robust response to vaccinations. None of the patients had a leukoproliferative event or clonal expansion. CONCLUSIONS: These long-term findings in a large patient cohort show the sustained clinical efficacy and safety of autologous CD34+ hematopoietic stem-cell lentiviral gene therapy for ADA-SCID, indicating that it is a curative treatment. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT04049084.).
引用
- Booth C, Masiuk K, Vazouras K, et al. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med. 2025. PMID: 41092330. doi:10.1056/NEJMoa2502754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。